ATE227120T1 - Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen - Google Patents

Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Info

Publication number
ATE227120T1
ATE227120T1 AT98921701T AT98921701T ATE227120T1 AT E227120 T1 ATE227120 T1 AT E227120T1 AT 98921701 T AT98921701 T AT 98921701T AT 98921701 T AT98921701 T AT 98921701T AT E227120 T1 ATE227120 T1 AT E227120T1
Authority
AT
Austria
Prior art keywords
testosterone
devices
precursor compounds
intravaginal administration
precursor
Prior art date
Application number
AT98921701T
Other languages
English (en)
Inventor
Clare Passmore
Claire Gilligan
Original Assignee
Galen Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galen Chemicals Ltd filed Critical Galen Chemicals Ltd
Application granted granted Critical
Publication of ATE227120T1 publication Critical patent/ATE227120T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT98921701T 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen ATE227120T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE970333 1997-05-07
PCT/IE1998/000033 WO1998050016A2 (en) 1997-05-07 1998-05-07 Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors

Publications (1)

Publication Number Publication Date
ATE227120T1 true ATE227120T1 (de) 2002-11-15

Family

ID=11041465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921701T ATE227120T1 (de) 1997-05-07 1998-05-07 Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen

Country Status (15)

Country Link
US (1) US6416780B1 (de)
EP (1) EP0981327B1 (de)
JP (1) JP2001524124A (de)
CN (1) CN1184957C (de)
AT (1) ATE227120T1 (de)
AU (1) AU741482B2 (de)
CA (1) CA2288046C (de)
DE (1) DE69809222T2 (de)
DK (1) DK0981327T3 (de)
ES (1) ES2187024T3 (de)
IL (1) IL132702A0 (de)
NO (1) NO995419L (de)
NZ (1) NZ501236A (de)
PT (1) PT981327E (de)
WO (1) WO1998050016A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
WO2003080018A1 (en) * 2002-03-27 2003-10-02 Galen (Chemicals) Limited Intravaginal matrix drug delivery devices
US8399013B2 (en) 2003-06-26 2013-03-19 Poly-Med, Inc. Partially absorbable fiber-reinforced composites for controlled drug delivery
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
AR056968A1 (es) 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
EP1933810B1 (de) * 2005-08-11 2012-10-10 Massachusetts Institute of Technology Vorrichtung und verfahren für intravesikale wirkstofffreisetzung
NZ572193A (en) 2006-03-31 2011-10-28 Quadra Logic Tech Inc Nasolacrimal drainage system implants for drug therapy with non-fluid swellable retention structure around drug core
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
JP5560200B2 (ja) 2007-12-11 2014-07-23 マサチューセッツ インスチテュート オブ テクノロジー 膀胱および他の身体の小嚢又は管腔を治療するための埋め込み型薬物供給デバイス
PT2249757T (pt) * 2008-02-04 2017-11-15 Ferring Bv Anéis intravaginais monolíticos compreendendo progesterona e métodos de preparação e suas utilizações
US9034365B2 (en) 2008-05-20 2015-05-19 Poly-Med, Inc. Biostable, multipurpose, microbicidal intravaginal devices
CN102176931B (zh) * 2008-08-09 2015-03-04 麻省理工学院 治疗男性泌尿生殖组织和外周组织的可植入药物递送设备和方法
WO2010045251A2 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals, Inc. Spiro-oxindole compounds and their use as therapeutic agents
CA2741024A1 (en) 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
ES2401008T3 (es) 2009-06-26 2013-04-16 Taris Biomedical, Inc. Comprimidos farmacéuticos sólidos para dispositivos implantables para la administración de fármacos
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
AU2010306768B2 (en) 2009-10-14 2016-08-04 Xenon Pharmaceuticals Inc. Synthetic methods for spiro-oxindole compounds
MY165117A (en) 2010-02-26 2018-02-28 Xenon Pharmaceuticals Inc Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
SG191893A1 (en) 2011-01-10 2013-08-30 Taris Biomedical Inc Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
RU2598057C2 (ru) 2011-02-04 2016-09-20 ТАРИС Биомедикал ЛЛК Имплантируемое устройство для контролируемого высвобождения лекарственного средства с низкой растворимостью
EP3120834A1 (de) 2011-08-29 2017-01-25 Mati Therapeutics Inc. Verzögerte freisetzung von wirkstoffen zur behandlung von glaukom oder okularer hypertonie
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
WO2013064983A1 (en) 2011-10-31 2013-05-10 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
SG11201507294WA (en) 2013-03-15 2015-10-29 Taris Biomedical Llc Drug delivery devices with drug-permeable component and methods
JP2016514459A (ja) 2013-03-15 2016-05-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 線維素溶解についての二重反応性の強力なクニッツ阻害剤
LT3035991T (lt) 2013-08-19 2020-11-10 Taris Biomedical Llc Daugiablokiai vaistų vartojimo įtaisai
CN104546668B (zh) * 2013-10-23 2019-03-05 国家卫生计生委科学技术研究所 液体硅橡胶为载体的药物缓控释系统的制备及应用
PL2982352T3 (pl) * 2014-06-28 2019-01-31 Laboratorios Andrómaco S.A. Krążek szyjki macicy zawierający progesteron do długotrwałego, przedłużonego i ciągłego uwalniania, stosowany w celu zapobiegania przed przedwczesnym porodem
AR103636A1 (es) 2015-02-05 2017-05-24 Teva Pharmaceuticals Int Gmbh Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
EP3285850A1 (de) 2015-04-23 2018-02-28 TARIS Biomedical LLC Wirkstoffabgabevorrichtungen mit einer wirkstoffdurchlässigen komponente und verfahren
PL3416964T3 (pl) 2016-02-19 2021-10-18 Phoenix Molecular Designs Pochodne 6-okso-n-(1-(benzylo)-1h-pirazol-4-ilo)-6,7,8,9-tetrahydropirydo[3’,2’:4,5]pirolo[1,2-a]pirazyno-2-karboksyamidu jako inhibitory kinazy rybosomalnej s6 p90 (rsk) do leczenia nowotworu złośliwego
ES3022639T3 (en) 2016-05-20 2025-05-28 Xenon Pharmaceuticals Inc Benzenesulfonamide compounds and their use as therapeutic agents
CN110325531B (zh) 2016-12-09 2022-05-27 泽农医药公司 苯磺酰胺及其作为治疗剂的用途
BR112020024729A2 (pt) 2018-06-13 2021-03-23 Xenon Pharmaceuticals, Inc. compostos de benzenossulfonamida e seu uso como agentes terapêuticos
KR20210061332A (ko) 2018-07-27 2021-05-27 제논 파마슈티칼스 인크. 뇌전증 치료 방법
IL279810B2 (en) 2018-08-31 2025-03-01 Xenon Pharmaceuticals Inc Heteroaryl-modified sulfonamide compounds and their use as medicinal agents
MA53488A (fr) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone
CN113677681A (zh) 2019-02-11 2021-11-19 凤凰分子设计公司 Rsk抑制剂的结晶形式
CA3232232A1 (en) 2021-09-24 2023-03-30 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
TW202322794A (zh) 2021-09-24 2023-06-16 加拿大商再諾製藥公司 做為鈉通道活化劑之吡啶基衍生物
KR20240070604A (ko) 2021-09-24 2024-05-21 제논 파마슈티칼스 인크. 소듐 채널 활성화제로서 피리디닐아세트아미드 유도체
EP4536356A1 (de) 2022-06-08 2025-04-16 Xenon Pharmaceuticals Inc. Pyridinaminderivate und ihre verwendung als kaliumkanalmodulatoren
WO2025024795A1 (en) 2023-07-27 2025-01-30 Neurocrine Biosciences, Inc. Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920805A (en) * 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
AU538961B2 (en) * 1980-06-09 1984-09-06 Alex Harvey Industries Limited Intra-vaginal device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
IL116433A (en) 1994-12-19 2002-02-10 Galen Chemicals Ltd INTRAVAGINAL DRUG DELIVERY DEVICES FOR THE ADMINISTRATION OF 17β-OESTRADIOL PRECURSORS

Also Published As

Publication number Publication date
CN1184957C (zh) 2005-01-19
ES2187024T3 (es) 2003-05-16
NZ501236A (en) 2002-02-01
CN1255056A (zh) 2000-05-31
WO1998050016A3 (en) 1999-02-04
JP2001524124A (ja) 2001-11-27
EP0981327A2 (de) 2000-03-01
CA2288046A1 (en) 1998-11-12
PT981327E (pt) 2003-02-28
NO995419D0 (no) 1999-11-05
CA2288046C (en) 2006-10-03
AU741482B2 (en) 2001-11-29
EP0981327B1 (de) 2002-11-06
DE69809222D1 (de) 2002-12-12
AU7446998A (en) 1998-11-27
US6416780B1 (en) 2002-07-09
DE69809222T2 (de) 2003-08-14
WO1998050016A2 (en) 1998-11-12
DK0981327T3 (da) 2003-03-10
NO995419L (no) 2000-01-07
IL132702A0 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
ATE227120T1 (de) Vorrichtungen zur intravaginalen verabreichung von testosteron und testosteron- vorläuferverbindungen
AU1227899A (en) Osmotic medicament releasing system
FI972586A7 (fi) Lääkeainesuspension säädellysti vapauttava antolaite
ID21259A (id) Sistim penyaluran obat untuk dua atau lebih bahan-bahan aktif
CA2298245A1 (en) Matrix controlled release device
GB2341550A (en) Gastroretentive controlled release microspheres for improved drug delivery
ES2192226T3 (es) Composicion farmaceutica oral que contiene agentes activos antimicrobianos y pantoprazol de liberacion prolongada.
EP1504758A3 (de) Formulierungen mit kontrollierter Abgabe überzogen mit wässrigen Dispersionen von Ethylcellulose.
PT1238660E (pt) Distribuicao sustentada de um agente activo utilizando um sistema implantavel
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
EP1466606A3 (de) Verwendung von Inosine zur Herstellung eines Medikamentes zur Stimulierung des Axonwachstums von ZNS-Neuronen
AU3990797A (en) Sustained release formulation
PT1017391E (pt) Formulacao de comprimidos de libertacao prolongada para tratar a doenca de parkinson
HRP20010684B1 (hr) Izravno stlaciva matrica za kontrolirano otpustanje jednostruke dnevne doze klaritromicina
FR2774288B1 (fr) Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
BR9902528A (pt) Sistema implantável e implante destinado à administração subcutânea ou local
BG108516A (en) Pharmaceutical formulation
AU1495595A (en) Sustained-release dosage forms of alfuzosin hydrochloride
WO1998026767A3 (en) Site-specific controlled release dosage formulation for mesalamine
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
MY129726A (en) Active ingredient combination (e.g. galanthamine or desoxypeganine with acamprosate or memantine) for treating a dependence on addictive substances or narcotics
DE69831940D1 (de) Tablette mit verlängerter Wirkstoffabgabe im Magen
EP1106609A3 (de) Aminoalkohol-Derivat und Medikament, das dieses Derivat enthält
NZ309697A (en) Novel formulation for peptide release
NZ324674A (en) Rapid release tablet comprising tolfenamic acid, alginic acid and a superdisintegrant

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0981327

Country of ref document: EP

REN Ceased due to non-payment of the annual fee